GLP-1 Agonists Linked to Nail Disorders: A Clinical Overview
03/10/2026
Recent research has demonstrated that users of GLP-1 receptor agonists exhibit a significantly higher likelihood of experiencing nail disorders, particularly
Aprobación de un nuevo parche de terapia hormonal genérico Recentemente, la FDA aprobó el primer genérico del sistema transdérmico de…
Read more →
Recent research has demonstrated that users of GLP-1 receptor agonists exhibit a significantly higher likelihood of experiencing nail disorders, particularly
Adults with type 2 diabetes experienced considerable weight loss with a new investigational combination treatment involving eloralintide and tirzepatide (Mounjaro,
El uso de agonistas del receptor GLP-1 alrededor del embarazo no parece aumentar los resultados adversos maternos o perinatales, según
Introducción The recent ACHIEVE-4 trial evaluated orforglipron (Foundayo), an oral GLP-1 receptor agonist, demonstrating cardiovascular safety though its heart benefits
The FDA designated Vitruvias Therapeutics’opens in a new tab or window recall of a lot of 30-mg levothyroxine-liothyronine tablets (Thyroid